全文获取类型
收费全文 | 1335134篇 |
免费 | 102119篇 |
国内免费 | 4282篇 |
专业分类
耳鼻咽喉 | 16810篇 |
儿科学 | 43610篇 |
妇产科学 | 36387篇 |
基础医学 | 198052篇 |
口腔科学 | 35917篇 |
临床医学 | 129832篇 |
内科学 | 258520篇 |
皮肤病学 | 26398篇 |
神经病学 | 112032篇 |
特种医学 | 48202篇 |
外国民族医学 | 366篇 |
外科学 | 184223篇 |
综合类 | 28786篇 |
现状与发展 | 1篇 |
一般理论 | 463篇 |
预防医学 | 114568篇 |
眼科学 | 28991篇 |
药学 | 98934篇 |
6篇 | |
中国医学 | 3172篇 |
肿瘤学 | 76265篇 |
出版年
2021年 | 10957篇 |
2019年 | 11681篇 |
2018年 | 16361篇 |
2017年 | 12328篇 |
2016年 | 13290篇 |
2015年 | 15233篇 |
2014年 | 20860篇 |
2013年 | 32153篇 |
2012年 | 44406篇 |
2011年 | 47037篇 |
2010年 | 27144篇 |
2009年 | 24984篇 |
2008年 | 42810篇 |
2007年 | 45148篇 |
2006年 | 45251篇 |
2005年 | 43679篇 |
2004年 | 41636篇 |
2003年 | 39571篇 |
2002年 | 38353篇 |
2001年 | 60868篇 |
2000年 | 62549篇 |
1999年 | 52306篇 |
1998年 | 14589篇 |
1997年 | 13280篇 |
1996年 | 13122篇 |
1995年 | 12461篇 |
1994年 | 11632篇 |
1993年 | 10926篇 |
1992年 | 41579篇 |
1991年 | 40782篇 |
1990年 | 39460篇 |
1989年 | 37357篇 |
1988年 | 34600篇 |
1987年 | 33710篇 |
1986年 | 32160篇 |
1985年 | 30644篇 |
1984年 | 23051篇 |
1983年 | 19599篇 |
1982年 | 11761篇 |
1979年 | 20814篇 |
1978年 | 14818篇 |
1977年 | 12068篇 |
1976年 | 11880篇 |
1975年 | 12115篇 |
1974年 | 14804篇 |
1973年 | 14474篇 |
1972年 | 13360篇 |
1971年 | 12425篇 |
1970年 | 11486篇 |
1969年 | 10414篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
161.
162.
163.
J. Oliveira-Santos R. Santos C. Moreira S. Abreu L. Lopes C. Agostinis-Sobrinho G. Stratton J. Mota 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(8):783-792
Background and aimsThe long-term relations between excessive adiposity in early childhood and unfavourable cardiometabolic profiles in later ages are not yet completely understood. We aimed to assess the associations between birth weight (BW) and BMI from 6 months to 6 years of age, with biomarkers indicative of low-grade inflammation, insulin resistance and lipid profiles in adolescence.Methods and resultsRetrospective school-based study with 415 Portuguese adolescents (220 girls), mean age of 14.08 ± 1.6 years old. Anthropometric data from birth to 6 years old was extracted from individual child health book records. Actual weight and height were measured and BMI calculated. Participants were classified at each time point as normal weight or overweight according to WHO reference values. Biomarkers were obtained from venous blood samples. Linear regressions were used to explore the associations between the biomarkers and early life anthropometric indicators. From 2 years onwards, BMI associated positively with the inflammatory score and HOMA-IR in adolescence. Children who were overweight/obese from 2 to 6 years of age presented significantly higher inflammatory score and HOMA-IR later in adolescence. TC/HDL ratio was also positively associated with BMI from the age of 5 years onwards. The associations between BMI and cardiometabolic outcomes remained positive in adolescence, with overweight adolescents presenting a higher inflammatory score, HOMA-IR and TC/HDL than normal weight adolescents.ConclusionA high BMI from an early age was consistently associated with worse inflammatory and lipid profiles and insulin resistance in adolescence. No associations were found between BW and the same studied outcomes. 相似文献
164.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献165.
166.
167.
Toidi Adekambi Chris C. Ibegbu Stephanie Cagle Ameeta S. Kalokhe Yun F. Wang Yijuan Hu Cheryl L. Day Susan M. Ray Jyothi Rengarajan 《The Journal of clinical investigation》2015,125(5):1827-1838
BACKGROUND. The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient’s sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.METHODS. Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment.RESULTS. Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment.CONCLUSION. We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure.TRIAL REGISTRATION. Registration is not required for observational studies.FUNDING. This study was funded by Emory University, the NIH, and the Yerkes National Primate Center. 相似文献
168.
169.